Evidence map›Paper›PMID 39647912›Full record

ArticleJournal of epidemiology2025

Colorectal Cancer Screening Based on Fecal Immunochemical Test and Risk Assessment: A Population-based Study Including Two Million Participants in China.

Dong Hang, Chen Zhu, Xiaolin Yang, Jinjin He, Huizhang Li, Tingting Pan, Le Wang, Shi Wang, Wei Wu, Jieming Zhong and 11 more

Abstract read
In one paragraph

Article in Journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Dong HangDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.ORCID 0000-0001-6944-0459
Chen ZhuDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.ORCID 0000-0002-4079-6491
Xiaolin YangDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Jinjin HeDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Huizhang LiDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Tingting PanDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Le WangDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Shi WangDepartment of Endoscopy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Wei WuDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Jieming ZhongDepartment of Chronic and Noncommunicable Disease Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention.
Weiwei GongDepartment of Chronic and Noncommunicable Disease Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention.
Meng ZhuDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Ci SongDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Hongxia MaDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Ni LiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Yanfei QiuDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Guangfu JinDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Zhibin HuDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.
Lingbin DuDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.ORCID 0000-0002-1992-7784
Xiangdong ChengDepartment of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences.
Hongbing ShenDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe fecal immunochemical test (FIT) has been widely used in colorectal cancer (CRC) screening, yet the practical performance of FIT combined with questionnaire-based risk assessment (QRA) remains undetermined. Moreover, risk factors for distinct CRC precursors identified in screening have been rarely compared.

methodsThis study was based on a population-based CRC screening in China, with 2,120,340 participants completing both FIT and QRA. Those with positive FIT or high QRA scores were recommended for colonoscopy. We reported the compliance, detection rate, and colonoscopy workload according to FIT and QRA results. We also explored risk factors for conventional adenomas and serrated polyps.

resultsThe compliance rate of colonoscopy in the subgroup of FIT (+) and QRA (+) was 41.4%, higher than the rates in FIT (+) and QRA (-), as well as FIT (-) and QRA (+), which were 38.7% (P < 0.001) and 16.4% (P < 0.001), respectively. The corresponding detection rates of advanced neoplasia were 18.2%, 13.2%, and 9.3% (all P < 0.001), respectively. Moreover, the required numbers of colonoscopies to detect one advanced neoplasia in the three subgroups were 5.5, 7.6, and 10.8, respectively. Increased body mass index, smoking, alcohol consumption, red meat intake, and type 2 diabetes were associated with higher risk of advanced adenomas and advanced serrated polyps, whereas vegetable intake was inversely associated with advanced adenomas.

conclusionFIT and QRA can synergistically identify individuals at high risk of colorectal advanced neoplasia, with those testing positive for both deserving immediate attention. Modifiable factors were identified to complement screening for preventing CRC precursors.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerFecesOccult BloodAdenomaAdultAgedChinaColonoscopyFemaleHumansMaleMiddle AgedPatient ComplianceRisk AssessmentRisk Factorscolonoscopycolorectal cancerfecal immunochemical testrisk assessmentscreening

Identifiers

PMID39647912
PMCPMC12066195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.